Prevalence and reasons for non-adherence to hyperlipidemia treatment

• Authors: Przemyslaw Kardas
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Adherence to medication; Patient compliance; Hyperlipidemia; Doctor-patient communication

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 5
• Pages: 539-547

Dates

published

1 - 10 - 2013

online

18 - 9 - 2013

Contributors

author

Przemyslaw Kardas

• Department of Family Medicine, Medical University of Lodz, 60 Narutowicza Str., 90-136, Lodz, Poland

References

• [1] Pajak A, Wiercinska E, Polakowska M, Kozakiewicz K, Kaczmarczyk-Chalas K, Tykarski A et al. Rozpowszechnienie dyslipidemii u mezczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63:6 (supl. 4); S1–6
• [2] Bandosz P, Flaherty M O’, Drygas W, Koziarek J, Wyrzykowski B, Rutkowski M et al. Explaining the decline in coronary heart disease mortality in Poland between 1991 and 2005. Eur Heart J. 2010, 31 (Abstract Suppl.), 167
• [3] Sabate E (red). Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003
• [4] Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152 http://dx.doi.org/10.1001/archinte.165.10.1147[Crossref]
• [5] Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–467 http://dx.doi.org/10.1001/jama.288.4.462[Crossref]
• [6] Wisniowska B, Skowron A. Evaluation of patients’ adherence to statins In Poland. Curr Med Res Opin. 2011; 27(1): 99–105 http://dx.doi.org/10.1185/03007995.2010.536745[Crossref]
• [7] Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009; 65(10): 1013–1024 http://dx.doi.org/10.1007/s00228-009-0673-0[WoS][Crossref]
• [8] Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297(2): 177–186 http://dx.doi.org/10.1001/jama.297.2.177[Crossref]
• [9] Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012 Jan;34(1):190–199 http://dx.doi.org/10.1016/j.clinthera.2011.12.011[Crossref]
• [10] Poluzzi E, Piccinni C, Carta P, Puccini A, Lanzoni M, Motola D et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol. 2011; 67(4): 407–414 http://dx.doi.org/10.1007/s00228-010-0958-3[WoS]
• [11] Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. Patient Prefer Adherence. 2012; 6: 323–329 http://dx.doi.org/10.2147/PPA.S29353[Crossref]
• [12] Vrijens B, De Geest S, Hughes DA, Kardas P, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, for the ABC Project Team. A new taxonomy for describing and defining adherence to medications. Brit J Clin Pharmacol 2012; 73(5), 691–705. DOI: 10.1111/j.1365-2125.2012.04167.x http://dx.doi.org/10.1111/j.1365-2125.2012.04167.x[Crossref]
• [13] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff 2011; 30(1): 91–99 http://dx.doi.org/10.1377/hlthaff.2009.1087[Crossref]
• [14] Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J. 2011; 32(3): 264–268 http://dx.doi.org/10.1093/eurheartj/ehq297[Crossref]
• [15] DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42(3): 200–209 http://dx.doi.org/10.1097/01.mlr.0000114908.90348.f9[Crossref]
• [16] Simpson RJ Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010; 4(6): 462–471 http://dx.doi.org/10.1016/j.jacl.2010.08.026[WoS][Crossref]
• [17] Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008; 14(6 Suppl B): 9–15
• [18] Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens. 1993; 11(12): 1403–1411 http://dx.doi.org/10.1097/00004872-199312000-00013[Crossref]
• [19] Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B; for the ABC project team. Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis. Drugs. 2013 Apr 16. DOI 10.1007/s40265-013-0041-3 [Crossref][WoS]
• [20] Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011; 107(11): 1662–1666 http://dx.doi.org/10.1016/j.amjcard.2011.01.052[WoS][Crossref]
• [21] Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes. Ann Pharmacother. 2011; 45(3): 342–349 http://dx.doi.org/10.1345/aph.1P539[Crossref]
• [22] Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy. 2001; 21(5): 576–582 http://dx.doi.org/10.1592/phco.21.6.576.34541[Crossref]

Identifiers

DOI

10.2478/s11536-013-0198-x